Synopsis

Clinical trial design and cancer drug development form a structured continuum that translates molecular discoveries into safe, effective patient therapies. Rooted in historical milestones and formalized under Good Clinical Practice (ICH-GCP) and ethical frameworks like the Declaration of Helsinki, this process balances methodological rigor with subject safety.

Human clinical trials systematically advance through four sequential phases: Phase I establishes human safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD); Phase II explores proof-of-concept and optimal dosing; Phase III confirms comparative efficacy and monitors adverse events in large, diverse populations for regulatory approval; and Phase IV conducts post-marketing pharmacovigilance and real-world safety surveillance.

In oncology, unique obstacles such as marked tumor heterogeneity, clonal evolution, and treatment resistance demand specialized trial structures. The paradigm has shifted from cytotoxic regimens toward precision oncology driven by biomarker validation, exposure-response modeling, and master protocols. Innovative frameworks, including basket and umbrella trials, allow parallel evaluation of targeted therapies across molecularly defined cohorts.

Supported by adaptive statistical designs, interim safety analyses, and holistic endpoints incorporating survival and quality-of-life metrics, modern oncology trials aim to accelerate drug innovation while preserving data integrity and public trust.

Key Highlights

About the Authors

Global Serviceability & Availability

Published & Printed by ThinkPlus Pharma Publications

Door No 9-15/1, Indrapalem, Kakinada, AP-533006, India

Website: www.books.jopir.in

Copyright © 2026 ThinkPlus Pharma Publications. All rights reserved. No part of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior written permission of the publisher.